对治疗急性双极性II型抑郁症的第二代抗抑郁药单疗法的系统审查
Ahmed Elmosalamy1, Nicola Keeth2, Jin Hong Park3
1Elmosalamy, MBBCh, Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Psychopharmacology bulletin
|July 9, 2025
概括
第二代抗抑郁药单一治疗对双相II型抑郁症具有前景,提供与相似的反应率,而不会增加切换风险. 需要进一步的研究来证实长期的有效性,并指导个性化治疗.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 双极性II型障碍 (BD-II) 的特点是经常出现抑郁症,FDA批准的治疗方法有限.
- 尽管如此,单氨基抗抑郁药经常被处方为BD-II抑郁症.
- 这凸显了基于证据的治疗选择的急需.
研究的目的:
- 系统地审查第二代抗抑郁药 (SGAD) 单疗法在治疗急性双相II型抑郁症方面的证据.
- 更新目前对这种患者群体SGAD疗效和安全性的理解.
主要方法:
- 从2021年3月到2025年2月,在多个数据库 (MEDLINE,Embase,CENTRAL,PsycINFO,Scopus,Web of Science) 中进行了全面的文献搜索.
- 包括的研究是随机对照试验 (RCT),评估急性BD-II抑郁症成人SGAD单疗法.
- 评估的主要结局包括反应,缓解,治疗出现的情感转换 (TEAS) 和不良事件 (AE) 相关的中止.
主要成果:
- 包括六个RCT (四个双盲,一个开放标签,一个三盲) 涉及666名患者.
- 文拉法辛和塞特拉林显示出短期有效性,反应率在60.4%-73.3%之间,缓解率在44.2%-58.5%之间.
- TEAS的风险低于19.9%,与相似;AE退出率相似,SGAD显示出可比或更好的所有原因停药率.
结论:
- 有限的短期数据表明,SGAD单疗对急性BD-II抑郁症的耐受性很好,反应率与相似,情绪转换风险没有增加.
- 目前的证据基础很小,异质,需要更大,更长期的RCT.
- 未来的研究应该专注于证实疗效,评估维持效益,并为BD-II抑郁症提供个性化治疗策略.
相关概念视频
Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Bipolar Disorder
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.


